# Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)

> **NCT06502249** · — · NOT_YET_RECRUITING · sponsor: **Ain Shams University** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer
- NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06502249
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06502249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06502249, "Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06502249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*